

Summary of Product Characteristics OPTILAST®

1. Name of the Medicinal Product

Optilast

0.5 mg/ml, Eye Drops, solution.

2. Qualitative and Quantitative Composition

Azelastine hydrochloride 0.05% (0.5 mg/ml). Each drop contains 0.015 mg azelastine hydrochloride.

Excipients with known effect: 1 ml contains 0.125 mg of Benzalkonium chloride.

For the full list of excipients, see section 6.1.

3. Pharmaceutical Form

Eye drops, solution.
Clear, colourless solution.

4. Clinical Particulars

4.1. Therapeutic Indications

Symptomatic treatment and prevention of seasonal allergic conjunctivitis.

4.2. Posology and Method of Administration

Seasonal allergic conjunctivitis:

Unless otherwise prescribed, the usual dosage in adults and children 4 years and older is one drop in each eye twice daily. This dosage can be increased, if necessary to up to four times daily.

If allergen exposure is, anticipated **Optilast** eye drops should be administered prophylactically, prior to the exposure.

Patients should be advised to contact their doctor if symptoms worsen or do not improve after 48 hours.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4. Special Warnings and Precautions for Use

Optilast is not intended for treatment of eye infections. Further warnings see 4.5 and 4.6.

Optilast eye drops contains the preservative benzalkonium chloride. Benzalkonium chloride may cause eye irritations, especially with dry eyes or disorders of the cornea. Contact with soft contact lenses should be avoided. Contact lenses should be removed prior to application and the patient should wait at least 15 minutes before reinsertion. Known to discolour soft contact lenses.

4.5. Interactions with other Medicaments and other forms of Interaction

No specific interaction studies with **Optilast** have been performed.

Interaction studies at high oral doses of Azelastine have been performed; however, they bear no relevance to **Optilast**, as systemic levels after administration of the eye drops, are in the picogram range.

4.6. Fertility, Pregnancy and Lactation

Fertility:

Effects on human fertility have not been investigated.

Pregnancy:

There is insufficient information available to establish the safety of azelastine in human pregnancy. At high oral doses azelastine has shown to induce adverse effects (foetal death, growth retardation and skeletal malformation) in experimental animals. Local ocular application will result in minimal systemic exposure (picogram range). However, caution should be exercised when using **Optilast** during pregnancy.

Breast-feeding:

Azelastine is excreted into the milk in low quantities. For that reason, **Optilast** is not recommended during lactation.

4.7. Effects on Ability to Drive and Use Machines

The mild, transient irritation, which can be experienced after application of **Optilast**, is unlikely to affect vision to any greater extent. However, if there are any transient effects on vision, the patient should be advised to wait until this clears before driving or operating machinery.

4.8. Undesirable Effects

The assessment of undesirable effects is based on the following frequencies:

Very common ($\geq 1/10$)

Common ($\geq 1/100$ to $< 1/10$)

Uncommon ($\geq 1/1000$ to $< 1/100$)

Rare ($\geq 1/10,000$ to $< 1/1000$)

Very rare ($< 1/10,000$)

Not known (cannot be estimated from the available data).

Immune system disorders

Very rare: Allergic reactions (such as rash and pruritus).

Nervous system disorders

Uncommon: Bitter taste.

Eye disorders

Common: Mild but transient irritation in the eye.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form <https://sideeffects.health.gov.il>

4.9. Overdose

No specific reactions after ocular overdose are known, and with the ocular route of administration, overdose reactions are not anticipated.

There is no experience with the administration of toxic doses of azelastine hydrochloride in humans. In the case of overdose or intoxication, disturbances of the central nervous system are to be expected based on the results of animal experiments. Treatment of these disorders must be symptomatic. There is no known antidote.

5. Pharmacological Properties

5.1. Pharmacodynamic Properties

Anti-allergic
ATC code: SO1GX07

Azelastine, a phthalazinone derivative is classified as a potent long-acting anti-allergic compound with selective H₁ antagonist properties. An additional anti-inflammatory effect could be detected after topical ocular administration.

Data from in vivo (pre-clinical) and in vitro studies show that azelastine inhibits the synthesis or release of the chemical mediators known to be involved in early and late stage allergic reactions e.g. leukotriene, histamine, PAF and serotonin.

To date, long term therapy ECG evaluations of patients treated with high oral doses of azelastine, have shown that in multiple dose studies, there is no clinically significant effect of azelastine on the corrected QT (QTc) interval.

No association of azelastine with ventricular arrhythmia or torsade de pointes was observed in over 3700 patients treated with oral azelastine.

Relief of symptoms of allergic conjunctivitis should be noticed after 15-30 minutes.

5.2. Pharmacokinetic Properties

General characteristics (systemic pharmacokinetics)

Following oral administration azelastine is rapidly absorbed showing an absolute bioavailability of 81%. Food has no influence on absorption. The volume of distribution is high indicating distribution predominantly into the periphery. The level of protein binding is relatively low (80-90%, a level too low to give concern over drug displacement reactions).

Plasma elimination half-lives after a single dose of azelastine are approximately 20 hours for azelastine and about 45 hours for the therapeutically active main metabolite N-Desmethyl azelastine. Excretion occurs mainly via the faeces. The sustained excretion of small amounts of the dose in the faeces suggests that some enterohepatic circulation may take place.

Characteristics in patients (ocular pharmacokinetics)

After repeated ocular application of **Optilast** eye drops (up to one drop in each eye, four times daily), C_{max} steady state plasma levels of azelastine hydrochloride were very low and were detected at or below the limit of quantification.

5.3. Preclinical Safety Data

Azelastine hydrochloride displayed no sensitizing potential in the guinea pig. Azelastine demonstrated no genotoxic potential in a battery of in vitro and in vivo tests, nor any carcinogenic potential in rats or mice.

In male and female rats, azelastine at oral doses greater than 3.0 mg/kg/day caused a dose-related decrease in the fertility index; no substance-related alterations were found in the reproductive organs of males or females during chronic toxicity studies, however.

Embryotoxic and teratogenic effects in rats, mice and rabbits occurred only at maternal toxic doses (for example, skeletal malformations were observed in rats and rabbits at doses of 68.6 mg/kg/day).

6. Pharmaceutical Particulars

6.1. List of Excipient(s)

Sorbitol solution 70%, Methylhydroxypropyl cellulose, Edetate Disodium Benzalkonium chloride, Sodium hydroxide, and Water for Injections.

6.2. Incompatibilities

Not applicable.

6.3. Shelf Life

Unopened: The expiry date of the product is indicated on the packaging materials.

Once opened: do not use for longer than 4 weeks after first opening.

6.4. Special Precautions for Storage

Store below 25°C

6.5. Nature and Contents of Container

10 ml opaque HDPE bottle and LDPE dropper with white HDPE screw cap.
One bottle contains 6 ml solution.

6.6. Instruction for Use/Handling

This medicinal product does not require any special storage conditions.

7. Manufacturer:

Meda Pharma GmbH & Co.KG, Bad Homburg, Germany

8. Marketing Authorisation Holder:

Megapharm LTD, PO. Box 519 Hod Ha'sharon 4510501, Israel

9. Marketing Authorisation Number

117-67-29826

Revised in February 2021 according to MOH guidelines.

OPT SPC 022021_P.1